Nonpartisan civic infrastructure
AllCiv·Legis1
·

S. 1176

BillFederalSenateIn Committee
Onshoring Essential Antibiotics Act
About This Bill
Committee
Latest Action · April 15, 2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Congress
117th (2021–2023)
Introduced
April 15, 2021
Cosponsors (1)
0D 1R
View PDF ↗

Summary

Highlight any text to annotate
Onshoring Essential Antibiotics Act This bill requires the Department of Health and Human Services (HHS) to provide grants to up to three manufacturers of essential generic antibiotic drugs (or of the active pharmaceutical ingredient or key starting material for such a drug). Under the bill, an essential generic antibiotic drug is one that HHS deems to be medically necessary to have available at all times in adequate amounts. These grants may be used to (1) construct, expand, or upgrade a manufacturing facility in the United States; and (2) manufacture essential generic antibiotic drugs. HHS shall commission a report with (1) recommendations about which drugs should be prioritized in the grant program, and (2) an analysis of the expected effect of domestic drug manufacturing on drug costs to consumers. HHS may stockpile essential generic antibiotic drugs manufactured in the United States. The bill provides in funding for the grant program and for HHS to stockpile generic antibiotic drugs.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.